Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

In exchange for at least 25% representation in Players Era, the Big 12 hopes to earn back big money on its commitment. "Over ...

Alphabet stock continues its surge on the back of excitement around Google’s latest large-language model, while Tesla rises ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...

An intimate bar and coffee area in the kitchen makes for a suitable backdrop for intimate gatherings, according to its listing. Spacious upper-level bedrooms have Jack-and-Jill baths. Other highlights ...

Seeking Alpha analysts have upgraded Nvidia (NVDA) and Alibaba (BABA), emphasizing their strategic positions in the AI and ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...